Booster; Severe coccyx / sacroiliac joint pain (tailbone area and hip) with second dose and third dose; Severe coccyx / sacroiliac joint pain (tailbone area and hip) with second dose and third dose; the pain / discomfort with vaccine 2+3 was significant enough to derail all my activities for multiple days; the pain / discomfort with vaccine 2+3 was significant enough to derail all my activities for multiple days; the pain / discomfort with vaccine 2+3 was significant enough to derail all my activities for multiple days; I had the sensation that my whole body was swollen; my spinal cord was inflamed; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 23Nov2021 14:00 (Batch/Lot number: unknown) at the age of 34 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "cephalosporins" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Unable to locate or read the details, Location of injection: Arm Right, Route of Administration: Intramuscular), administration date: 09Apr2021, when the patient was 34 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 2, Batch/Lot No: Unknown. Unable to locate or read the details, Location of injection: Arm Right, Route of Administration: Intramuscular), administration date: 30Apr2021, when the patient was 34 years old, for COVID-19 immunization, reaction(s): "Severe coccyx / sacroiliac joint pain (tailbone area and hip) with second dose and third dose", "Severe coccyx / sacroiliac joint pain (tailbone area and hip) with second dose and third dose", "the pain / discomfort with vaccine 2+3 was significant enough to derail all my activities for multiple days", "the pain / discomfort with vaccine 2+3 was significant enough to derail all my activities for multiple days", "the pain / discomfort with vaccine 2+3 was significant enough to derail all my activities for multiple days". The following information was reported: Myelitis (medically significant) with onset 23Nov2021, outcome "recovering", described as "my spinal cord was inflamed"; IMMUNISATION (non-serious) with onset 23Nov2021 14:00, outcome "unknown", described as "Booster"; ARTHRALGIA (non-serious), SACRAL PAIN (non-serious) all with onset 23Nov2021, outcome "recovering" and all described as "Severe coccyx / sacroiliac joint pain (tailbone area and hip) with second dose and third dose"; PAIN (non-serious), DISCOMFORT (non-serious), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) all with onset 23Nov2021, outcome "recovering" and all described as "the pain / discomfort with vaccine 2+3 was significant enough to derail all my activities for multiple days"; SWELLING (non-serious) with onset 23Nov2021, outcome "recovering", described as "I had the sensation that my whole body was swollen". Therapeutic measures were not taken as a result of spinal cord disorder, discomfort, loss of personal independence in daily activities, swelling. Therapeutic measures were taken as a result of arthralgia, sacral pain, pain.  Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.  The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Based on the information currently available, a possible contributory role of the suspect vaccine BNT162B2 or Comirnaty in triggering the onset of Myelitis, booster, arthralgia, sacral pain ,pain, discomfort, loss of personal independence in daily activity , swelling  cannot be excluded. But also consider medical history of pyrexia and wheezing associated with influenza vaccine.